ArticleFrontiers in immunology2026
Multi-omics investigation of perineural invasion in head and neck squamous cell carcinoma: neuroimmune mechanisms and clinical implications.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perineural invasion (PNI) is an aggressive feature in head and neck squamous cell carcinoma (HNSCC), but its molecular basis and neuroimmune implications, including potential links to immunotherapy response, remain unclear. Methods: We performed an integrative multi-omics analysis using public datasets and an independent clinical cohort. Transcriptomic, proteomic, single-cell, and spatial transcriptomic data were jointly analyzed to identify PNI-associated molecular patterns, construct prognostic signatures, and characterize immune infiltration and cell-cell communication. Regulatory elements were further explored by super-enhancer mapping and target-gene prediction. Pharmacologic inhibition experiments using the TLR2 inhibitor C29 were performed in FaDu cells for functional validation. Results: PNI was associated with extracellular matrix and neuroactive signaling changes. A protein-based signature (ADIPOQ, MB, PLIN1, ADH1B) stratified survival risk. PNI-positive/high-risk tumors showed an immune-suppressed phenotype with lower predicted immunotherapy sensitivity and reduced CD8+ T-cell, B-cell, and Tfh-cell infiltration. Spatial analysis showed higher PNI scores at the invasive front, positive correlations with neural programs, and enrichment of TLR2-related signaling. TLR2 expression was associated with the PNI score, neural markers, and immune exclusion. In FaDu cells, C29 suppressed proliferation, migration, and invasion. Super-enhancer analysis identified candidate SE-target genes, including MYL4, CMYA5, and TNNT3, linked to PNI-associated biology. Conclusions: PNI in HNSCC is associated with coordinated extracellular-matrix, neuroimmune, and immune-suppressive remodeling. These findings support PNI-related molecular signatures for risk stratification and identify TLR2-related signaling and SE-associated programs as candidate mechanisms for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.